Ozmosi | Vincristine Drug Profile

Product Description

Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)

Mechanisms of Action: Mitosis Inhibitor, Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Premier Inc
Company Location:
Company CEO:
Additional Commercial Interests: Pfizer

Clinical Description

Map of Global Clinical Trials for Vincristine

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 31

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04681417	RETINO2018	P3	Recruiting	Retinoblastoma	2035-01-20		2024-11-27	Primary Endpoints\|Treatments
NCT06072131	CRESCENDO	P3	Recruiting	T-Cell Peripheral Lymphoma	2030-07-01	18%	2024-11-27
2018-003335-29	2018-003335-29	P3	Active, not recruiting	Other	2029-10-15		2022-03-13	Treatments
NCT05848765	REFRACT	P2	Recruiting	Follicular Lymphoma	2029-05-31	78%	2024-11-27
NCT06709495	NCT06709495	P2	Recruiting	Osteosarcoma\|Primitive Neuroectodermal Tumors\|Sarcoma, Ewing\|Small Cell Sarcoma\|Desmoplastic Small Round Cell Tumor\|Peripheral Neuroectodermal Tumors, Primitive\|Rhabdomyosarcoma	2028-11-01	12%	2025-02-14
NCT06738368	RG1124788	P2	Not yet recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Leukemia\|Acute Lymphoid Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	2027-12-31	2%	2024-12-19	Primary Endpoints\|Treatments
NCT04043494	LBL 2018	P3	Recruiting	Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin	2027-11-22		2024-11-27
NCT06954805	AAAV2404	P2	Recruiting	Lymphoma, B-Cell\|Lymphoproliferative Disorders	2027-04-14		2025-05-03	Primary Endpoints\|Treatments
NCT03117751	TOT17	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-09-30	7%	2024-11-27	Primary Endpoints\|Treatments
NCT02684708	EuroNet-PHL-C2	P3	Active, not recruiting	Hodgkin Lymphoma	2026-09-30		2021-05-14	Primary Endpoints\|Treatments\|Trial Status
NCT04980222	GO43075	P2	Active, not recruiting	Lymphoma	2026-09-30	12%	2025-11-19	Primary Completion Date\|Primary Endpoints\|Treatments
NCT05280626	CIBI308Y047	P2	Not yet recruiting	Diffuse Large B-Cell Lymphoma	2025-12-31	54%	2024-11-27	Primary Endpoints\|Treatments
ACTRN12622000173796p	SBSDS	P2	Not yet recruiting	Pregnancy Outcomes\|Pregnancy Complications, Infectious\|COVID-19\|Fetal Diseases	2022-12-31
NCT04307576	ALLTogether1	P3	Recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2033-06-01	59%	2025-08-29
NCT06947967	SWIFT 02	P3	Recruiting	T-Cell Peripheral Lymphoma	2032-12-01	33%	2025-09-16	Primary Completion Date\|Primary Endpoints\|Start Date\|Treatments\|Trial Status
2019-004153-93	2019-004153-93	P3	Active, not recruiting	Sarcoma, Ewing	2030-12-17		2025-06-19	Treatments
NCT06356129	GOLSEEK-1	P3	Recruiting	Lymphoma, B-Cell	2028-08-14	16%	2025-08-27
NCT06533748	SJALL23H	P2	Recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2028-05-01	2%	2025-01-11
NCT03643276	AIEOP-BFM ALL 2017	P3	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2028-07-14		2024-11-27	Primary Endpoints
NCT03755804	cHOD17	P2	Active, not recruiting	Hodgkin Lymphoma	2027-01-01	2%	2025-09-23
NCT03020030	NCT03020030	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-11-30	38%	2025-01-04
NCT06921044	CSPC-DED-DLBCL-K15	P2	Not yet recruiting	Diffuse Large B-Cell Lymphoma	2026-02-01	12%	2025-04-11	Primary Endpoints\|Treatments
CTR20192684	CTR20192684	P3	Completed	Diffuse Large B-Cell Lymphoma	2025-06-29		2025-11-02
NCT03467373	NP40126	P1	Completed	Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin	2024-12-02	41%	2025-01-18	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT03206671	B-NHL 2013	P3	Recruiting	Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin	2024-08-01		2025-03-27	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
12/08/2025	News Article	Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
12/02/2025	News Article	Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
11/14/2025	News Article	Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
09/25/2025	News Article	Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Vincristine

Alternative Names: vincristine, vincristina, marqibo, oncovin, Vincristine Sulfate, vincristin, vincasar pfs, vincrex Clinical Status: Inactive Latest Update: 2025-12-08 Latest Update Note: News Article